Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 21 · below the Ichimoku cloud · RSI 39 · MACD above its signal
| 47.40 | 52-week high | +72.74% |
| 29.90 | Previous month high | +8.97% |
| 28.47 | R3 (classic) | +3.75% |
| 28.34 | Previous week high | +3.28% |
| 28.20 | R2 (classic) | +2.77% |
| 27.93 | Previous day high | +1.79% |
| 27.82 | R1 (classic) | +1.38% |
| 27.55 | Pivot | +0.40% |
| 27.44 | Price now | |
| 27.28 | Previous day low | −0.58% |
| 27.17 | S1 (classic) | −0.98% |
| 27.15 | Previous week low | −1.06% |
| 26.90 | S2 (classic) | −1.97% |
| 26.52 | S3 (classic) | −3.35% |
| 25.81 | Previous month low | −5.94% |
| 23.01 | 52-week low | −16.14% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $4.2M | 0.01% | 99.70K | −20% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ELMD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Nagel Bradley M.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 4.9K | — |
| Jun 7, 2026 | Cunniff James L.Chief Executive Officer | Sale at price 36.25 - 37.77 per share. | 9.7K | $354.10K |
| Jun 7, 2026 | Cunniff James L.Chief Executive Officer | Conversion of Exercise of derivative security at price 17.25 per share. | 9.7K | $167.32K |
| Jun 3, 2026 | Nagel Bradley M.Chief Financial Officer | Sale at price 36.34 - 37.11 per share. | 11.8K | $428.94K |
| Jun 3, 2026 | Nagel Bradley M.Chief Financial Officer | Conversion of Exercise of derivative security at price 10.25 - 10.71 per share. | 9.6K | $100.83K |
| May 14, 2026 | Skarvan Kathleen SDirector | Sale at price 34.36 - 37.33 per share. | 40K | $1.42M |
| May 14, 2026 | Skarvan Kathleen SDirector | Conversion of Exercise of derivative security at price 3.82 per share. | 40K | $152.80K |
| Nov 30, 2025 | Skarvan Kathleen SDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Nov 30, 2025 | Fluet Gregory JDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Nov 30, 2025 | Tune Kathleen ADirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Nov 30, 2025 | Erickson Stan KDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Nov 30, 2025 | Walsh Andrea MDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Nov 30, 2025 | Galatowitsch Joseph LDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Sep 1, 2025 | Nagel Bradley M.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 5.3K | — |
| Sep 1, 2025 | Cunniff James L.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 17K | — |
| Feb 17, 2025 | Skarvan Kathleen SDirector | Sale at price 29.15 - 33.08 per share. | 76.6K | $2.33M |
| Feb 13, 2025 | Skarvan Kathleen SDirector | Conversion of Exercise of derivative security at price 1.80 per share. | 40K | $72.00K |
| Dec 30, 2024 | Cunniff James L.Chief Executive Officer | — | 87.5K | — |
| Nov 28, 2024 | Skarvan Kathleen SDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Nov 28, 2024 | Fluet Gregory JDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
TimeframesDown on the hourly and daily, mixed on the weekly and monthly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.6 | -20.7 | -1.2 | 9.8 | 46.7 | 12.1 | -3.7 | -31.3 | 0.9 | -2.8 | −5.8% | ||
| 2025 | 16.4 | -21.4 | -11.8 | -3.5 | -12.3 | 8.9 | -17.2 | 35.8 | -0.7 | -2.0 | 11.3 | 8.8 | −1.5% |
| 2024 | -7.9 | 51.2 | 6.2 | 7.7 | -15.9 | 2.8 | 4.1 | 9.7 | 25.2 | 8.3 | 32.4 | -4.0 | +170.9% |
| 2023 | 2.9 | 23.5 | -22.0 | 5.3 | 6.8 | -8.4 | -4.8 | -2.7 | 4.7 | 1.3 | -2.4 | 6.1 | +4.0% |
| 2022 | -0.4 | -5.3 | 1.5 | 1.8 | -11.0 | -14.5 | -6.4 | 7.5 | 5.7 | 3.6 | -5.9 | 5.0 | −19.3% |
| 2021 | 1.3 | 6.2 | -0.2 | -7.3 | 0.9 | 14.5 | 4.0 | 5.9 | -13.0 | 1.5 | 9.5 | 8.2 | +32.5% |
| 2020 | 12.6 | 5.6 | 9.2 | 24.5 | 3.1 | 6.7 | 7.8 | -25.4 | -15.9 | -20.2 | 21.4 | -2.8 | +13.4% |
| 2019 | 11.8 | -7.6 | -2.1 | 10.7 | -14.9 | 12.4 | -2.2 | 6.6 | 16.4 | 2.1 | 46.1 | -12.3 | +69.9% |
| 2018 | -7.4 | 3.2 | -7.6 | -0.4 | -12.7 | 16.3 | -3.1 | -11.2 | 39.5 | -0.9 | -11.5 | -10.7 | −16.1% |
| 2017 | 2.1 | 23.7 | 0.6 | -3.0 | -10.5 | 29.2 | 11.4 | 15.1 | 3.1 | 1.1 | -26.8 | 12.2 | +56.4% |
| 2016 | -14.7 | 200.6 | -14.8 | 10.6 | -8.3 | -8.3 | 15.3 | 21.1 | -14.8 | -11.3 | -4.9 | 0.3 | +104.2% |
| 2015 | -14.2 | 5.2 | 4.1 | -2.8 | -16.0 | -9.8 | -2.7 | -4.4 | 4.7 | 13.3 | 5.4 | -11.6 | −28.8% |
| 2014 | -50.0 | -1.8 | -16.2 | -10.7 | -5.6 | 20.3 | 6.3 | -6.0 | 25.4 | -9.0 | 42.0 | 16.1 | −21.5% |
| 2013 | 0.0 | 29.6 | -17.1 | -6.9 | -4.4 | -1.6 | -3.1 | -19.5 | 8.1 | -6.5 | 10.0 | 209.1 | +151.9% |
| 2012 | -13.0 | -3.3 | 0.0 | -6.6 | -15.1 | -8.7 | -4.8 | -8.5 | -20.8 | 4.1 | 17.2 | -23.7 | −60.9% |
| 2011 | -3.4 | 2.0 | -5.7 | 1.5 | 11.6 | -11.8 | 3.0 | 2.6 | 0.3 | 14.0 | -6.3 | -7.8 | −2.8% |
| 2010 | 1.9 | -5.7 | 2.9 | -1.4 | −2.5% |
Buy / hold / sell counts
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company provides SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.